Isofol Medical Logo

Isofol Medical

Developing a drug to enhance chemotherapy efficacy for solid tumors like colorectal cancer.

ISOFOL | ST

Overview

Corporate Details

ISIN(s):
SE0009581051
LEI:
549300MCXYAHG7VBHX75
Country:
Sweden
Address:
C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company develops its primary drug candidate, arfolitixorin, with the aim of increasing the efficacy of first-line standard chemotherapy treatments for various solid tumors. A key area of development is colorectal cancer, where the company is conducting a Phase Ib/II clinical study to optimize the drug candidate's dosing regimen and therapeutic effect.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:00
Quarterly Report
Swedish 11.9 MB
2025-11-12 08:00
Quarterly Report
English 12.0 MB
2025-11-04 09:45
Board/Management Information
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
English 454.1 KB
2025-11-04 09:45
Board/Management Information
Isofol har utsett valberedning inför årsstämman 2026
Swedish 377.2 KB
2025-09-23 10:45
Major Shareholding Notification
Swedish 10.5 KB
2025-08-26 08:00
Interim Report
Swedish 7.2 MB
2025-08-26 08:00
Interim Report
English 2.6 MB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Nytt antal aktier och röster i Isofol
Swedish 60.6 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Isofol
English 61.3 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofol's rights issue fully subscribed – exercises overallotment for Japanese p…
English 128.5 KB
2025-07-04 18:00
Share Issue/Capital Change
Isofols företrädesemission övertecknad – utnyttjar övertilldelning till japansk…
Swedish 127.3 KB
2025-06-17 08:40
Prospectus
Isofol offentliggör prospekt i samband med bolagets företrädesemission
Swedish 98.7 KB
2025-06-17 08:40
Prospectus
Isofol publishes prospectus in connection with the company’s rights issue
English 119.6 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on…
English 94.5 KB
2025-06-11 14:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Isofol Medical AB (publ) den 11 juni 2025
Swedish 74.5 KB

Automate Your Workflow. Get a real-time feed of all Isofol Medical filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Isofol Medical

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Isofol Medical via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-11 Magnus Hurst Other Buy 35,000 24,150.00 SEK
2022-09-12 AB Windar Other Buy 500,000 305,000.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 858.00 SEK
2021-12-09 Tony Gustavsson Other Sell 58,767 152.79 SEK
2021-06-14 HealthCom GmbH Other Buy 233,336 1,493,350.40 SEK
2021-06-10 Gustaf Albèrt Other Other 15,153 96,979.20 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 43,487.58 SEK
2020-11-23 Tony Gustavsson Other Buy 58,767 29,971.17 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 43,487.58 SEK
2020-11-16 Sven Eriksson Other Sell 58,767 29,971.17 SEK

Peer Companies

Bestone.Com Co.,Ltd Logo
An online travel agency specializing in domestic and overseas cruise tours and tickets.
Japan
6577
BeyondSpring Inc. Logo
Develops innovative immuno-oncology cancer therapies, including a 'pipeline in a drug' asset.
United States of America
BYSI
bioAffinity Technologies, Inc. Logo
Develops noninvasive diagnostics for cancer, including an early lung cancer sputum test.
United States of America
BIAF
BIO-FD&C CO.,LTD. Logo
Develops plant cell-derived active ingredients for food, drug, and cosmetic industries.
South Korea
251120
BioNexus Gene Lab Corp Logo
Develops non-invasive, blood-based RNA tests for early cancer detection and risk assessment.
United States of America
BGLC
Biophytis S.A. Logo
Clinical-stage biotech developing drugs for age-related neuromuscular and retinal diseases.
France
ALBPS
BioSenic SA Logo
Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.
Belgium
BIOS
BIOTECH Logo
Biotech group offering preclinical zebrafish testing & intein tech for human/animal health.
Spain
BST
BiotoxtechCo.,Ltd. Logo
A non-clinical CRO providing GLP-compliant safety and toxicity testing for diverse industries.
South Korea
086040
Bolt Biotherapeutics, Inc. Logo
Developing immunotherapies that use antibody conjugates to help the immune system destroy cancer.
United States of America
BOLT

Talk to a Data Expert

Have a question? We'll get back to you promptly.